ARGXargenx SE

$1,046.73

$637.5652 weeks$1.0K

Price

$1,046.73+56%1Y

1M+13%1Y+56%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

7/10

Value39

Quality-

Momentum71

Growth87

Strongest Growth, weakest Value · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Our legal and commercial name is argenx SE. From incorporation until August 28, 2009, our research and development activities were initially performed in the Netherlands, then Belgium, by argenx N.V. and its legal predecessors. Since August 28, 2009, all our research and development activities have been performed by our wholly-owned subsidiary, argenx BV, under a license provided by argenx N.V.

In the company’s own words · 20-F filed Mar 19, 2026 · SEC EDGAR

P/E (TTM)53.5

Market Cap$54.85B

1Y Return+56%

5Y Return+239%

argenx SE (ARGX) reported revenue of $2.47B in H2 2025 (quarter ended December 31, 2025), up 226% from the same quarter a year earlier. That came with a gross margin of 90% and net income of $877M (35% of revenue). For the full year FY2025, revenue was $4.25B (+89% year on year) and net income $1.29B.

Raw charts

10 series · TTM

As reported to the SEC, without any scoring.

Biotechnology

Ranks #75 of 145 by Smart Score

Compare peers

REGN+0.87%

Regeneron Pharmaceuticals

ALNY-0.30%

Alnylam Pharmaceuticals, Inc.

RVMD+4.9%

Revolution Medicines, Inc.

Vertex Pharmaceuticals